



PATENT
ATTORNEY DOCKET NO. SCRIP1460

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hugli, et al. Art Unit: To be assigned
Serial No.: 09/922,236 Examiner To be assigned
Filed: August 2, 2001
Title: DIAGNOSTIC MARKERS OF LIVER DYSFUNCTION

Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL SHEET

Sir:

Transmitted herewith for the above-identified application, please find:

- (1) An Information Disclosure Statement (2 pages);
- (2) A Form PTO-1449 (5 pages);
- (3) Thirty-seven (37) Reference Articles; (323 pages)
- (4) Return postcard.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on this date, **November 13**, 2001 in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231.

JASON BERRY
Name of Person Mailing Paper
Jason Berry
Signature

In the Application of
Hugli, et al.
Application Serial No.: 09/922,238
Filed: August 2, 2001




PATENT
Attorney Docket No.: SCRIP1460

No fee is deemed necessary in connection with the filing of this paper. However, if any fee is required, the Commissioner is hereby authorized to charge the amount of the fee, or credit any overpayments, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: 11/13/01



Lisa A. Haile, Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, California 92121-2133

United States Patent & Trademark Customer No. 28213



PATENT
Attorney Docket No. SCRIPI460

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Hugli, et al.	Art Unit:	Unassigned
Serial No.:	09/922,236	Examiner:	Unassigned
Filed:	August 2, 2001		
Title:	DIAGNOSTIC MARKERS OF LIVER DYSFUNCTION		

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. 1.97, enclosed are references relating to the above-identified application. For the convenience of the Examiner, these references are listed on the attached Form PTO-1449 and a copy of each is enclosed herewith.

It is respectfully requested that these references be considered in the examination of this application and their consideration be made of written record in the application file.

CERTIFICATION UNDER 37 CFR §1.8

I hereby certify that the documents referred to as enclosed herein are being deposited with the United States Postal Service as first class mail on November 13, 2001, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

Jason Berry

Applicant: Hugli, et al
Serial No.: 09/922,236
Filed: August 2, 2001



PATENT
Attorney Docket No. SCRIP1460

This Information Disclosure Statement is being filed prior to the receipt of a First Office Action on the merits. Therefore, no fee is deemed necessary in connection with this filing. However, if any fee is required, authorization is hereby given to charge the amount of any such fee, or credit any overpayment, to Deposit Account No. 50-1355.

Respectfully submitted,

Date: 11/12/01

A handwritten signature in cursive script that reads "Lisa A. Haile".

Lisa A. Haile, Ph.D.
Registration No. 38,347
Telephone: (858) 677-1456
Facsimile: (858) 677-1465

GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121-2133

U.S. Patent & Trademark Office Customer No. 28213

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: SCRI1460	Application No.: 09/922,236
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicants: Hugli, et al.	
	Filing Date: August 2, 2001	Group Art Unit: Not Yet Assigned

4	AD	Chenoweth, D.E., S.W. Cooper, T.E. Hugli, R.W. Stewart, E.H. Blackstone, and J.W. Kirklin. 1981. Complement activation during cardiopulmonary bypass: evidence for generation of C3a and C5a anaphylatoxins. <i>N. Engl. J. Med.</i> 304:497-503
5	AE	Cooper, N.R. 1998. Complement and viruses. <i>In</i> The Human Complement System in Health and Disease. J.E. Volanakis and M.M. Frank, editors. Marcel Dekker, Inc., New York. 393-407
6	AF	Craddock, P.R. J. Fehr, K.L. Brigham, R.S. Kronenberg, and H.S. Jacob. 1977. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. <i>N. Engl. J. Med.</i> 296:769-774
7	AG	Drouet, C., L. Bouillet, F. Csoopaki, and M.G. Colomb. 1999. Hepatitis C virus NS3 serine protease interacts with the serpin C1 inhibitor. <i>FEBS Lett.</i> 458:415-418
8	AH	Franco, A.G. and P.H. Schur. 1971. Hypocomplementemia in rheumatoid arthritis. <i>Arthritis Rheum.</i> 14:231-238
9	AI	Hack, C.E., J.H. Nuijens, R.J. Felt-Bersma, W.O. Schreuder, A.J. Erenberg-Belmer, J. Paardekooper, W. Bronsveld, and L.G. Thijs. 1989. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with fatal outcome in sepsis. <i>Am. J. Med.</i> 86:20-26
10	AJ	Hammerschmidt, D.E., P.R. Craddock, J. McCullough, R.S. Kronenberg, A.P. Dalmasso, and H.S. Jacob. 1978. Complement activation and pulmonary leukostasis during nylon fiber filtration leukapheresis. <i>Blood</i> 51:721:730
11	AK	Harpel, P.C. and M.F. Lewin. 1985. Distribution of plasma kallikrein between C1 inactivator and α_2 -macroglobulin in plasma utilizing a new assay for α_2 -macroglobulin-kallikrein complexes. <i>J. Biol. Chem.</i> 260:4257-4263
12	AL	Hayashi, J. and T.E. Hugli. 2000. Kallikrein-like activity associated with α -2-macroglobulin (α -2-M) in plasma from liver transplant recipients. <i>Protein Science</i> 9:462-T.(Abstr.)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: SCRIP1460	Application No.: 09/922,236
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Applicants: Hugli, et al.	
	Filing Date: August 2, 2001	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

EXAM. INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

FOREIGN PATENT DOCUMENTS


EXAM. INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION (YES/NO)

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	AA	Atkinson, J.P. 1986. Complement activation and complement receptors in systemic lupus erythematosus. <i>Semin. Immunol. Pathol.</i> 9:179-194
	AB	Budzko, D.B., V.A. Bokisch, and H.J. Muller-Eberhard. 1971. A fragment of the third component of human complement with anaphylatoxin activity. <i>Biochemistry.</i> 10:1166-1172.
	AC	Buyon, J.P., J. Tamerius, S. Ordorica, B. Young, and S.B. Abramson. 1992. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. <i>Athritus Rheum.</i> 35:55-61

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: SCRIP1460	Application No.: 09/922,236
	Applicants: Hugli, et al.	
	Filing Date: August 2, 2001	Group Art Unit: Not Yet Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		


13	AM	Hayashi, J., D.R. Salomon, and T.E. Hugli. Elevated kallikrein activity in plasma from stable liver transplant recipients. <i>Arterioscler. Thromb. Vasc. Biol.</i> , in press
14	AN	Heideman, M. and T.E. Hugli. 1984. Anaphylatoxin generation in multisystem organ failure. <i>J. Trauma</i> 24:1038-1043
15	AO	Hitomi, Y. and S. Fujii. 1982. Inhibition of various immunological reactions <i>in vivo</i> by a new synthetic complement inhibitor. <i>Int. Arch. Allergy Appl. Immunol.</i> 69:262-267
16	AP	Ikari, N., Y. Hitomi, and S. Fujii. 1983. New synthetic inhibitor to the alternative complement pathway. <i>Immunology.</i> 49:685-691.
17	AQ	Kaufman, N., J.D. Page, R.A. Pixley, R. Schein, A.H. Schmaier, and R.W. Colman. 1991. α_2 -Macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. <i>Blood.</i> 77:2660-2667
18	AR	Kirschfink, M., T. Wienert, K. Rother, and S. Pomer. 1992. Complement activation in renal allograft recipients. <i>Transplantation Proceedings.</i> 24:2556-2557
19	AS	Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. <i>Nature.</i> 227:680-685
20	AT	Love, R.A., H.E. Parge, J.A. Wickersham, Z. Hostomsky, N. Habuka, E.W. Moomaw, T. Adachi, and Z. Hostomska. 1996. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site. <i>Cell.</i> 87:331-342
21	AU	Moon, K.E., J.P. Gorski, and T.E. Hugli. 1981. Complete primary structure of human C4a anaphylatoxin. <i>J. Biol. Chem.</i> 256:8685-8692.
22	AV	Motta, G., R. Rojkaer, A.A.K. Hasan, D.B. Cines, and A.H. Schmaier. 1998. High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. <i>Blood.</i> 91:516-528
23	AW	Moxley, G. and S. Ruddy. 1987. Elevated plasma C3 anaphylatoxin levels in rheumatoid arthritis patients. <i>Arthritis Rheum.</i> 30:1097-1104

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: SCRIP1460	Application No.: 09/922,236
	Applicants: Hugli, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: August 2, 2001	Group Art Unit: Not Yet Assigned


	AX 24	Nusbacher, J., S.I. Rosenfeld, J.L. MacPherson, P.A. Thiem and J.P. Leddy. 1978. Nylon fiber leukapheresis: associated complement component changes and granulocytopenia. <i>Blood</i> . 51:359-365
	AY 15	Patrick, R.A., S.B. Taubman, and I.H. Lepow. 1970. Cleavage of the fourth component of human complement (C4) by activated C1s. <i>Immunochemistry</i> . 7:217-225
	AZ	Petry, F. and M. Loos. 1998. Bacteria and complement. <i>In the Human Complement System in Health and Disease</i> . J.E. Volanakis and M.M. Frank, editors. Marcel Dekker, Inc. New York. 375-391.
	BA	Pfeifer, P.H., J.J. Brems, M. Brunson, and T.E. Hugli. 2000. Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study. <i>Immunopharmacology</i> . 46:163-174
	BB	Pfeifer, P.H., M. Kawahara, and T.E. Hugli. 1999. Possible mechanism for <i>in vitro</i> complement (C) activation in blood and plasma samples: Futhan/EDTA controls <i>in vitro</i> complement activation. <i>Clin. Chem</i> . 45:1190-1199
	BC	Reid, K.B.M. 1998. Clq and mannose-binding lectin. <i>In the Human Complement System in Health and Disease</i> . J. Volanakis and M. Frank, editors. Marcel Dekker, Inc., New York. 33-48
	BD	Renaux, J.L., M. Thomas, T. Crost, N. Loughraieb, and G. Vantard. 1999. Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. <i>Kidney Int</i> . 55:1097-1103
	BE	Ronholm, E., H. Tomasdottir, J. Runeborg, A. Bengtsson, J.P. Bengtson, O. Stenqvist, and S. Friman. 1994. Complement system activation during orthotopic liver transplantation in man. <i>Transplantation</i> 57:1594-1597.
	BF	Schapira, M., C.F. Scott, and R.W. Colman. 1982. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. <i>J. Clin. Invest</i> . 69:462-468.
	BG	Schenkein, H.A. 1991. The role of complement in periodontal diseases. <i>Crit. Rev. Oral Biol. Med</i> . 2:65-81

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449

FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office	Docket No.: SCRIP1460	Application No.: 09/922,236
	Applicants: Hugli, et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date: August 2, 2001	Group Art Unit: Not Yet Assigned

	BH	Scholz, T.L., Blackman, O. Mathisen, L. Buo, T. Karlsrud, H.T. Johansen, A. Bergan, G.B. Klintmalm, and A.O. Aasen. 1995. Activation of the plasma ciontact system and hemodynamic changes after graft revascularization in liver transplantation. <i>Transplantation</i> 60:36-40
	BI	Teitel, J.M., K.A. Bauer, H.K. Lau, and R.D. Rosenberg. 1982. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F1/F1+2 fragment and thrombin-antithrombin complex. <i>Blood</i> 59:1086-1097.
	BJ	Veloso, D., L. Silver, S. Hahn, and R.W. Colman. 1987. A monoclonal anit-human plasma prekallilrein antibody that inhibits activation of prekillkrein by factor XIIa on a surface. <i>Blood</i> 70:1053-1062
	BK	Violi, F., D. Ferro, S. Basili, M. Artini, G. Valesini, M. Levrero, and C. Cordova. 1995. Increases rate of thrombin generation in hepatitis C virus cirrhotic patients. relationship to venous thrombosis. <i>J. Invest. Med.</i> 43:550-554.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form 1449